<style face="normal" font="default" size="100%">757 Phase 1/2a clinical trial of BI-1808, a monoclonal antibody to tumor necrosis factor receptor 2 (TNFR2) as single agent and in combination with pembrolizumab</style>

Drupal-HighWire